Now Playing
Opinion|Videos|January 16, 2026
Treatment Selection Post–CDK4/6 Inhibition in Advanced ER+ Breast Cancer
Author(s)Hope S. Rugo, MD, FASCO, Seth Wander, MD, PhD
Hope S. Rugo, MD, and Seth Wander, MD, PhD, discuss treatment selection after CDK4/6 inhibitor progression in advanced ER-positive breast cancer.
Advertisement
Episodes in this series
Hope S. Rugo, MD, and Seth Wander, MD, PhD, discuss treatment selection strategies for patients with advanced estrogen receptor–positive breast cancer following progression on CDK4/6 inhibitors. They review how endocrine sensitivity, prior therapies, and molecular features influence next-line decision-making. Rugo and Wander also highlight the growing role of oral SERDs in combination with targeted agents.
Advertisement
Related to this article
Divesiran lowered phlebotomy needs, raised ferritin, and improved MPN-10 symptom scores in phlebotomy-dependent polycythemia vera.
A Dana-Farber study identified an RNA surveillance defect that fuels melanoma through endogenous retroviral RNA.
Belantamab mafodotin–based therapy improved sustained MRD negativity rates in relapsed/refractory multiple myeloma.
Updated COMMANDS data showed durable RBC transfusion independence and a positive overall survival trend with luspatercept in lower-risk MDS.
Robert A. Winn, MD, discussed his path to becoming a physician, scientist, and leader at Fox Chase Cancer Center.
Updated analyses from a phase 2a study suggest durable survival with namodenosen in a subset of heavily pretreated patients with advanced PDAC.
Need a refresh on the current regulatory landscape for GI oncology? We've got you covered. Here's everything that moved the needle across GI malignancies this month.
Toni Choueiri, MD, discusses the clinical significance of the FDA approval of adjuvant belzutifan plus pembrolizumab in ccRCC.
Advertisement
Advertisement
Trending on OncLive
1
Luspatercept Sustains Long-Term Transfusion Independence, Favorable OS Trend in ESA-Naive Lower-Risk MDS
2
Study Identifies RNA Surveillance Defect That Fuels Melanoma Through Endogenous Retroviral RNA
3
Belantamab Mafodotin Yields Sustained MRD Negativity in R/R Myeloma
4
FDA Grants Breakthrough Device Designation to Merlin CP-GEP for Early-Stage Melanoma Risk Stratification
5